Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Yeah, I just hope that FDA doesn't do similar crap as they did with HIV, that is we complete the study with 350mg and then they want another study on 700mg...
Nope, but several posters have emailed the company; at least one should get through and get an answer...
It's sticked at the other board :)
When FDA is confronted with a highly efficacious drug with no SAE:
https://homdor.com/work/blondspryarkshell/detail
But only temporarily and not to 0 as your shoe scam :)
That would explain too why the meeting for the pivotal phase 3 has been pushed down further and further down the road...
Though perhaps he would have hinted at the possibility that FDA might been looking into a possible label expansion without a further trial...
Hi Terry, good to have your expertise back, lol.
Continue pumping OncoSec and Conatus :)
Inoviorulez Friday, 08/23/19 10:30:37 PM
Re: penniestodimes post# 45175 0
Post #
45215
of 55291
This stock CYDY is toast. Lawsuit will take much needed capital, company is barely hanging on by a thread.
Agree. Likely Won't be able to vote with my shares since I'm from Europe, but I'd encourage everyone to vote against this absurdly high bonus compensation...
"Looking for revenue to hit not
heavy catalysts +
heavy promotion"
Then you should exit that shoe scam stock with $300 revenue and stoo pumping.
"Big Nasdaq could give them the right valuations"
Exactly. 3b should do it until year-end.
Excellent choice shorting that turd RBNW! I 100% agree.
Well, ohm pointed out the MOA that can help here. It will be investigated, nothing more, nothing less. All the data and papers as to CCR5 are out there for everyone to find and read.
It would be pumping if it was totally absurd that leronlimab could help, which it isn't, or if they had stated it provided a cure, which they didn't.
They simply linked the useful (getting attention), with the right (investigating a promising molecule for something where there is current need).
To be fair, even the likes of Gilead and J&J issued similar releases like candy...
Thanks! If RBNW had bought CYDY shares at .30 with their $300 revenue, they could have more than tripled their profits!
I 100% agree!
And despite all this "cult followers drinking the kool-aid" (or, in your opinion, who follow the science which you don't bother to understand) are up more than 100% because they averaged down, unlike you clown, hahahahahahahaha! Ouch!
Yes, really unheard of that Phase 3 biotechs have a 1b+ market cap... Yawn...
Quick, you need to rehash that article with ViiV's HIV drug!
Admin/Mods: why is spamming tolerated and recycled while normal posts get deleted? LieHub mafia at work again?
Next, he will copy&paste a link of a HIV med approved in 1996 and write "Competition is ahead of us!"
In my experience, people who write in bold and put ten exclamation marks after a sentence are hardly credible and don't have any arguments...
They will sell shoes that inject leronlimab through a special micro-needle delivery system! Even Beyonce will wear them! Check it out! They are about to merge with a huge oil company too! Watch out! Dilution no problem!
BOOOYA BOOOYA! (Sorry, keyboard is writing itself!)
Man, now I need to figure out whom to take off from my "ignore list" in order to block you... Tough decision ahead. Hm...
Yeah, it is unheard of in biotech that companies with a great pipeline/platform drug and close to approval in a multi-billion market trade higher than 300m... lol...
It's fine as long as they don't put a hefty price tag on leronlimab as that Shkreli did with other drugs.
I do trust that they stick with 30-60k for HIV and that a certain price has been negotiated so that the biggest possible number of patients may benefit!
"Shkreli is the former CEO of Turing Pharmaceuticals, which in 2015 raised the price of the drug Daraprim by 5,000%, from $13.50 per dose to $750 (cutting it to a mere $375 for some hospitals, after an outcry). The drug treats infections from toxoplasmosis, which can be fatal in patients also suffering from AIDS."
Yes, I grant you that the thing with the big banks is one of my all-time favourites too.
Probably the conditions were shares at .10 with 300% warrant coverage.
Anyway it is lame to have seen all those multiple offers and opportunities fallen through. Has raised my skepticism and I need to see the BLA submitted now and a deal closed...
Well, market tells us that it wants to see more results: more patients over a longer period of time.
While the signs of efficacy are extremely encouraging, only results of a way higher number of patients over a longer period of time will show a clear picture...
That's why it's important that they enroll as many patients as they can as fast as possible...
...and don't forget about all the introductions for the CCs!
True story, lol.
The payments are due on approval, not submission as I see it, except for 500k to AbbVie
Pursuant to the Progenics Purchase Agreement, we are required to pay Progenics a
remaining milestone payment and royalties as follows: (i) $5,000,000 at the time of the first U.S. new drug application approval by the FDA or other
non-U.S. approval for the sale of PRO 140;
Payments to Progenics are in addition to payments due under a Development and License Agreement, dated April 30, 1999 (the “PDL License”),
between Protein Design Labs (now AbbVie Inc.) and Progenics, which was assigned to us in the Progenics Purchase Agreement, pursuant to which we
have an exclusive worldwide license to develop, make, have made, import, use, sell, offer to sell or have sold products that incorporate the humanized
form of the PRO 140 antibody developed under the agreement. Pursuant to the PDL License, we are required to pay AbbVie Inc. remaining milestone
payments and royalties as follows: (i) $500,000 upon filing a Biologic License Application with the FDA or non-U.S. equivalent regulatory body;
(ii) $500,000 upon FDA approval or approval by another non-U.S. equivalent regulatory body; and (iii) royalties of up to 3.5% of net sales for the longer of
10 years and the date of expiration of the last to expire licensed patent. Additionally, the PDL License provides for an annual maintenance fee of $150,000
until royalties paid exceed that amount. To the extent that such remaining milestone payments and royalties are not timely made, under the terms of the
PDL License, AbbVie Inc. has certain termination rights relating to our license of PRO 140 thereunder.
Effective July 29, 2015, we entered into a License Agreement (the “Lonza Agreement”) with Lonza Sales AG (“Lonza”) covering Lonza’s “system
know-how” technology with respect to our use of proprietary cell lines to manufacture new PRO 140 material. The Lonza Agreement provides for an
annual license fee and future royalty payments, both of which varies based on whether Lonza, or we or our strategic partner manufactures PRO 140. We
currently use an independent party as a contract manufacturer for PRO 140. Therefore, if this arrangement continues, an annual license fee of £300,000
(approximately US$365,000 given current exchange rate) would continue to apply, as well as a royalty, up to 2% of the net selling price upon
commercialization of PRO 140, excluding value added taxes and similar amounts.
Yes, slowly I've come to believe this too... If no deal + BLA by end of December our situation will look dire, despite all the progress that has been made...
No, that's the Level 2 code for: "Lmao, let's make Amarin iHub go crazy speculating"
Lol. Yes, prequels were disappointing and sequels are a disaster (on par with CYDY SP)... 4 5 6 the best..
For the record, the force lightning was NOT deadly! Maul was killed "again" by Obi-Wan on Tatooine though...
Here it is
I am sure everyone here is aware of the risks involved in OTC and biotech stocks abd have a well diversified portfolio.
You can still get in, and at a much better price than two years ago when you sold!
Well, he said so much during a dozen interviews over the last months that one would need to check when he said what about the deal and up-front...
.20, since it becomes clear that no patients will be enrolled in the cancer trials? :D ;)
It was due end of October, not September. Well, it was repeated in the last interviews that it's still alive.